A Strategy for Value-Based Drug Pricing Under the Inflation Reduction Act
To make sure that CMS is getting its money’s worth for today’s drugs, it must ensure that the maximum fair price is aligned to drug value.
Alternatives To The QALY For Comparative Effectiveness Research
We now have useful and valid alternatives that allow for the assessment and valuation of treatments that improve population health without discriminating against vulnerable patient populations.
Comments to CMS on the Inflation Reduction Act’s Drug Price Negotiation Program
Over 20 researchers cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations for the Medicare Drug Price Negotiation Program
Health Technology Assessment in the U.S. – A Vision for the Future
Health technology assessment (HTA) can help achieve the dual health policy goals of ensuring affordability and encouraging innovation.Categorized in